International Stem Cell (OTCMKTS:ISCO) Share Price Crosses Above 200-Day Moving Average of $0.00

Shares of International Stem Cell Corp (OTCMKTS:ISCO) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.00 and traded as high as $0.71. International Stem Cell shares last traded at $0.71, with a volume of 7 shares changing hands.

Separately, Zacks Investment Research raised shares of International Stem Cell from a “sell” rating to a “hold” rating in a research report on Tuesday, August 6th.

The firm has a market capitalization of $5.35 million, a PE ratio of -2.15 and a beta of 0.71. The company has a quick ratio of 0.46, a current ratio of 0.79 and a debt-to-equity ratio of 0.32. The stock’s 50-day moving average is $0.87.

International Stem Cell (OTCMKTS:ISCO) last posted its earnings results on Friday, May 17th. The biotechnology company reported ($0.12) EPS for the quarter. International Stem Cell had a negative return on equity of 52.75% and a negative net margin of 12.51%. The firm had revenue of $2.22 million for the quarter. Research analysts predict that International Stem Cell Corp will post -0.39 earnings per share for the current fiscal year.

About International Stem Cell (OTCMKTS:ISCO)

International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes.

Further Reading: How interest rates affect municipal bond prices

Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.